Tiny Float Biotech With Multiple 2026 Catalysts

This cancer diagnostics microcap is trading around $0.91, up 7.5% today. The US 2k-patient eAArly DETECT 2 colorectal study is enrolling, which could set up a pivotal FDA trial next year. Early pancreatic cancer data already shows 100% sensitivity and 95% specificity, which is rare for early detection research.

The company raised $6M recently and regained Nasdaq compliance, giving it cash to fund trials and expand commercial operations. European ColoAlert expansion and lab partnerships in Switzerland and the UK give the story commercial credibility alongside clinical progress.

World news supports this sector: governments globally are pushing early detection programs, and multi-cancer screening using blood-based biomarkers is becoming a hot focus for research and investment. With a tiny float under 20M shares, any positive headlines could spark sharp intraday swings.

Which 2026 milestone are you most watching clinical readouts, regulatory milestones, or conference presentations? Not financial advice.